Skip to main content

Table 1 Demographic data and patient characteristics

From: Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry

Variable Caspofungin monotherapy
(N = 36)
Caspofungin combination therapy
(N = 6)
Total
(N = 42)
Gender, n (%)    
   Male 22 (61%) 2 (33%) 24 (57%)
   Female 14 (39%) 4 (67%) 18 (43%)
Age (years; median (range)) 59 (20 to 75) 42 (17 to 57) 57 (17 to 75)
Affected organ, n    
   Lung 35 6 41
   Trachea 1 0 1
Neutropenic status at start of caspofungin therapy    
Neutrophilic granulocytes < 500/μL 27 (75%) 1 (17%) 28 (67%)
Neutrophilic granulocytes ≥ 500/μL 9 (25%) 5 (83%) 14 (33%)
No. of risk factors per patient
(median (range))
5 (3 to 9) 7 (3 to 7) 5 (3 to 9)
Risk factors, n (%)*'    
   Active cancer 35 (97%) 4 (67%) 39 (93%)
   Immunosuppressive therapy 34 (94%) 5 (83%) 39 (93%)
   Neutropenia at hospitalization 26 (72%) 1 (17%) 27 (64%)
   Allogeneic HSCT 5 (14%) 3 (50%) 8 (19%)
   Prior colonization with fungi 5 (14%) 1 (17%) 6 (14%)
   Acute renal disease 4 (11%) 1 (17%) 5 (12%)
   Diabetes mellitus 4 (11%) 1 (17%) 5 (12%)
   Autologous HSCT 4 (11%) 0 4 (10%)
   AIDS/HIV disease 3 (8%) 0 3 (7%)
  1. *Odered by frequency. 'Multiple answers possible. HSCT hematopoetic stem cell transplantation